Is AGEN a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

926 people get AGEN articles and Market Currents by email alert.

Get email alerts on AGEN »

HEADLINES:

Agenus Announces Initiation of Enrollment in NCI-Sponsored Randomized Trial of Prophage G-200 Vaccine With Avastin in Treatment of Brain Tumors

GlobeNewswire (Wed, 7:00AM)
Positive Phase 2 Data from Agenus' Brain Cancer Vaccine Presented at Plenary Session of American Academy of Neurological Surgeons Meeting

GlobeNewswire (May 1, 2013)
Agenus: Near-Term Drivers With A Market Opportunity Over $17 Billion
Scott Matusow • Mon, Apr 29 • 16 Comments
Agenus' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Wed, Apr 24
Quickly Approaching Biopharma Catalyst Events
Scott Matusow • Wed, Apr 24 • 22 Comments
Agenus Reports First Quarter 2013 Financial Results

GlobeNewswire (Apr 24, 2013)
An Industry Outlook With Analyst Vernon Bernardino
Brian Nichols • Mon, Apr 22 • 5 Comments
Agenus to Report First Quarter 2013 Financial Results on April 24, 2013; Conference Call to Follow

GlobeNewswire (Apr 18, 2013)
Agenus Eliminates Its $39 Million Senior Notes and Completes $10 Million of New Debt Financing

GlobeNewswire (Apr 16, 2013)
Agenus' Brain Cancer Vaccine Results to be Presented at Plenary Session of the 81st American Association of Neurological Surgeons (AANS) Annual Scientific Meeting

GlobeNewswire (Apr 10, 2013)
3 Contenders With Novel, Non-Invasive Treatments For Cancer
The Swiss Trader • Mon, Apr 1 • 2 Comments
Survival Strategies For Development Biotechs And How They Affect Share Prices
Ryan's View • Thu, Mar 28 • 9 Comments
Agenus' Management Presents at Roth Annual Presentation Conference (Transcript)
Mon, Mar 18
Agenus to Present at the ROTH Annual Conference

GlobeNewswire (Mar 14, 2013)
Agenus' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Feb 28
Agenus Reports Fourth Quarter and Year End 2012 Financial Results

GlobeNewswire (Feb 28, 2013)
Agenus' HerpV Phase 2 Study to Treat Genital Herpes Completes Enrollment

GlobeNewswire (Feb 27, 2013)
Agenus to Present at Cowen and Company Annual Healthcare Conference

GlobeNewswire (Feb 26, 2013)
Agenus to Report Fourth Quarter and Year End 2012 Financial Results on February 28, 2013; Conference Call to Follow

GlobeNewswire (Feb 21, 2013)
Agenus to Present at BIO CEO & Investor Conference

GlobeNewswire (Feb 6, 2013)

To learn more about Seeking Alpha Pro, click here.

Agenus: Near-Term Drivers With A Market Opportunity Over $17 Billion
Scott Matusow • Mon, Apr 29 • 16 Comments
Agenus Inc: More Than Just A Stimulon Play
VFC's Stock House • Thu, Jul 19, 2012 • 2 Comments
Agenus: Buy Or Ready To Bust?
VFC's Stock House • Tue, Apr 3, 2012 • 1 Comment
Agenus Continues to Outperform
Prohost Biotech • Fri, Mar 16, 2012 • 1 Comment
Agenus Still Gaining On GSK Agreement Expansion
VFC's Stock House • Thu, Mar 15, 2012
Agenus May Be For Real Again
VFC's Stock House • Tue, Mar 13, 2012 • 2 Comments
Add Agenus To The Growing List Of Buyout Candidates
VFC's Stock House • Wed, Mar 7, 2012
Antigenics: Bright Future Ahead
VFC's Stock House • Wed, Jul 28, 2010 • 8 Comments
Antigenics Sees Encouraging Results; Good Long Term Pick
VFC's Stock House • Wed, May 26, 2010 • 4 Comments
Antigenics Should Rise on the Promise of Cancer Immunotherapy Treatments
VFC's Stock House • Tue, Oct 27, 2009 • 8 Comments
Pick Up Antigenics at a Bargain Price
VFC's Stock House • Thu, Oct 22, 2009 • 22 Comments
Have to Like the Risk / Reward in Antigenics Stock
VFC's Stock House • Sun, Sep 27, 2009 • 9 Comments
Antigenics: Why So Many Shorts?
VFC's Stock House • Tue, Sep 15, 2009 • 6 Comments
Antigenics' Current Price Is Irresistible
VFC's Stock House • Sun, Sep 6, 2009 • 3 Comments
Antigenics May Finally Be Back on the Uptick
VFC's Stock House • Wed, Sep 2, 2009 • 1 Comment
Feuerstein Comments on Antigenics: Weak at Best
VFC's Stock House • Thu, Aug 6, 2009 • 15 Comments
Antigenics: The Big Boys Are Buying
VFC's Stock House • Mon, Aug 3, 2009 • 4 Comments
Understanding Antigenics' Private Placement
VFC's Stock House • Sun, Aug 2, 2009 • 4 Comments
Antigenics: Why I Couldn't Resist Buying on the Dip
VFC's Stock House • Wed, Jun 24, 2009 • 3 Comments
Antigenics: A Gift at $2
VFC's Stock House • Mon, Jun 8, 2009 • 7 Comments

Quickly Approaching Biopharma Catalyst Events
Scott Matusow • Wed, Apr 24 • 22 Comments
An Industry Outlook With Analyst Vernon Bernardino
Brian Nichols • Mon, Apr 22 • 5 Comments
3 Contenders With Novel, Non-Invasive Treatments For Cancer
The Swiss Trader • Mon, Apr 1 • 2 Comments
Survival Strategies For Development Biotechs And How They Affect Share Prices
Ryan's View • Thu, Mar 28 • 9 Comments
Glaxo's Genital Herpes Vaccine Flops But Genocea's Next-Generation Approach Makes It A Buy
Rex Graham • Sun, Dec 16, 2012 • 6 Comments
7 Innovative Biotechs That Could Soar By Year-End: George Zavoico
Life Sciences Report • Thu, Sep 13, 2012 • 1 Comment
3 Vaccine Companies With Upcoming Catalysts - Part II
Markus Aarnio • Wed, Sep 12, 2012 • 2 Comments
5 Highly Liquid Biotech Stocks Positively Correlated To Volatility
Kapitall • Mon, Aug 27, 2012 • 3 Comments
Small-Cap Adjuvants For Cancer Treatment
The Swiss Trader • Sat, Jul 28, 2012 • 1 Comment
Amarin Moving Big And Other Healthcare Sector Notes
VFC's Stock House • Thu, Jul 19, 2012 • 6 Comments
All-Star Stocks
Markos Kaminis • Wed, Jul 11, 2012 • 8 Comments
Russell 3000 U.S. Healthcare Additions For June 2012
EXPstocktrader • Mon, Jun 11, 2012 • 2 Comments
Weekly Stock Watch: Week Of June 11, 2012
VFC's Stock House • Mon, Jun 11, 2012
Russell Index Additions To Create Upside While Shares Are Acquired In Open Market
Brian Nichols • Mon, Jun 11, 2012 • 8 Comments
5 Biotech Stocks That Could Be Included In The Russell 2000
Brian Nichols • Mon, Jun 4, 2012 • 20 Comments
Weekly Stock Watch: Week Of June 4, 2012
VFC's Stock House • Mon, Jun 4, 2012
ImmunoCellular Therapeutics ICT-107 To Impress At ASCO 2012
Chemistfrog • Fri, Jun 1, 2012 • 8 Comments
Critical Success Factors For The Immunotherapy Race
Andrew J. Norris • Thu, May 17, 2012 • 9 Comments
7 Outperforming Healthcare Stocks With Strong Insider Buying
Kapitall • Wed, May 16, 2012 • 1 Comment
Update On 26 Stocks For the Week Of May 14
VFC's Stock House • Sun, May 13, 2012 • 2 Comments

Agenus' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Wed, Apr 24
Agenus' Management Presents at Roth Annual Presentation Conference (Transcript)
Mon, Mar 18
Agenus' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Feb 28
Agenus' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Sat, Oct 27, 2012
Agenus' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Fri, Aug 3, 2012 • 1 Comment
Agenus' CEO Discusses Q4 2011 Results - Earnings Call Transcript
Mon, Mar 5, 2012
Agenus' CEO Discusses Q2 2011 Results - Earnings Call Transcript
Fri, Jul 29, 2011
Antigenics CEO Discusses Q4 2010 Results - Earnings Call Transcript
Thu, Feb 17, 2011 • 1 Comment
Antigenics CEO Discusses Q3 2010 Results - Earnings Call Transcript
Fri, Oct 29, 2010 • 1 Comment
Antigenics Inc. Q2 2010 Earnings Call Transcript
Thu, Jul 29, 2010
Antigenics Inc. Q1 2010 Earnings Call Transcript
Thu, Apr 29, 2010
Antigenics Q3 2009 Earnings Call Transcript
Thu, Oct 29, 2009
Antigenics, Inc. Q2 2009 Earnings Call Transcript
Thu, Jul 30, 2009
Antigenics Q4 2008 Earnings Call Transcript
Thu, Feb 19, 2009

Agenus Announces Initiation of Enrollment in NCI-Sponsored Randomized Trial of Prophage G-200 Vaccine With Avastin in Treatment of Brain Tumors

GlobeNewswire (Wed, 7:00AM)
Positive Phase 2 Data from Agenus' Brain Cancer Vaccine Presented at Plenary Session of American Academy of Neurological Surgeons Meeting

GlobeNewswire (May 1, 2013)
Agenus Reports First Quarter 2013 Financial Results

GlobeNewswire (Apr 24, 2013)
Agenus to Report First Quarter 2013 Financial Results on April 24, 2013; Conference Call to Follow

GlobeNewswire (Apr 18, 2013)
Agenus Eliminates Its $39 Million Senior Notes and Completes $10 Million of New Debt Financing

GlobeNewswire (Apr 16, 2013)
Agenus' Brain Cancer Vaccine Results to be Presented at Plenary Session of the 81st American Association of Neurological Surgeons (AANS) Annual Scientific Meeting

GlobeNewswire (Apr 10, 2013)
Agenus to Present at the ROTH Annual Conference

GlobeNewswire (Mar 14, 2013)
Agenus Reports Fourth Quarter and Year End 2012 Financial Results

GlobeNewswire (Feb 28, 2013)
Agenus' HerpV Phase 2 Study to Treat Genital Herpes Completes Enrollment

GlobeNewswire (Feb 27, 2013)
Agenus to Present at Cowen and Company Annual Healthcare Conference

GlobeNewswire (Feb 26, 2013)
Agenus to Report Fourth Quarter and Year End 2012 Financial Results on February 28, 2013; Conference Call to Follow

GlobeNewswire (Feb 21, 2013)
Agenus to Present at BIO CEO & Investor Conference

GlobeNewswire (Feb 6, 2013)
Agenus to Present at OneMedForum San Francisco 2013

GlobeNewswire (Jan 2, 2013)
Agenus to Present at Windhover's Therapeutic Area Partnerships Conference

GlobeNewswire (Nov 26, 2012)
Efficacy Shown With GlaxoSmithKline's Phase 3 Malaria Vaccine Candidate, Which Contains Agenus' Qs-21 Stimulon(R) ADJUVANT

GlobeNewswire (Nov 9, 2012)
Agenus Reports Third Quarter 2012 Financial Results

GlobeNewswire (Oct 25, 2012)
Agenus Commences Phase 2 Study of HerpV Vaccine for the Treatment of Genital Herpes

GlobeNewswire (Oct 23, 2012)
Agenus to Report 3rd Quarter Financial Results on October 25, 2012; Conference Call to Follow

GlobeNewswire (Oct 18, 2012)
Agenus to Present at 3rd Annual Cancer Immunotherapy Conference

GlobeNewswire (Sep 28, 2012)
Agenus to Present at the NewsMakers in the Biotech Industry Conference and the Rodman & Renshaw Global Investment Conference

GlobeNewswire (Sep 4, 2012)

AGEN vs. ETF Alternatives

Company Description

Agenus Inc. is a biotechnology company working to develop treatments for cancers and infectious diseases. The company is focused on immunotherapeutic products based on strong platform technologies with multiple product candidates advancing through the clinic, including several product candidates... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, April 24, 8:49 AM Agenus (AGEN): Q1 EPS of -$0.35 misses by $0.12. (PR) Comment! [Earnings, Breaking News]
Sunday, April 14, 10:48 PM The rest of the top 25 June deletions from the Russell 2000 expected by Credit Suisse: QUIK, IVAC, TINY, DSCO, RLOG, RMTI, AGEN, MSPD, DRL, AXTI, ELON, GYRO, CDZI, IQNT, BSCT, UAMY, MTSN, AUMN, URZ, INOD. ''IQNT is one of the more well-owned deletes among small cap funds," says CS. Comment! [Quick Ideas]
Wednesday, April 10, 10:14 AM Agenus (AGEN +4.1%) trades higher early after announcing Orin Bloch, clinical instructor in the Department of Neurological Surgery at the University of California San Francisco, will present data on the company's brain cancer vaccine at the American Association of Neurological Surgeon's annual meeting this month. Comment! [Healthcare, On the Move]
Thursday, March 7, 8:30 AM Northwest Biotherapeutics (NWBO +2%) expects to complete the enrollment of a 312-patient Phase III trial for its Glioblastoma multiforme brain cancer drug by Q1 or early Q2 next year. NW Bio says its recruitment is faster or more efficient than that for rival drugs, including for treatments from Celldex (CLDX), Immunocellular (IMUC) and Agenus (AGEN). (PR) 1 Comment [Healthcare]
Thursday, February 28, 7:11 AM Agenus (AGEN): Q4 EPS of -$0.23 beats by $0.01. Revenue of $1.09M beats by $370K. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, November 9, 2012, 8:54 AM Agenus (AGEN) +7.3% premarket after announcing efficacy shown with GlaxoSmithKline's (GSK) Phase 3 malaria vaccine candidate, which contains AGEN's Qs-21 Stimulon adjuvant. Infants at the trial receiving the vaccine experienced one-third fewer episodes of both clinical and severe malaria. Comment! [Healthcare, On the Move]
Tuesday, October 18, 2011, 1:20 PM Agenus (AGEN +50%) skyrockets after the company reports a Phase 3 trial of GlaxoSmithKline's (GSK) malaria vaccine, which contains an Agenus drug agent, found the vaccine delivered positive results. Agenus is entitled to milestone payments for the vaccine, as well as "royalties for 10 years after commercial launch." 1 Comment [Healthcare, On the Move]
Thursday, May 19, 2011, 9:05 AM Premarket gainers: GLUU +8%. AGEN +7%. MPEL +6%. PETM +5%. PAL +4%. IRE +4%. REE +4%. MCP +4%. TMO +4%. EXEL +3%. DLTR +3%. BCS +3%.
Losers: SMT -20%. BIG -9%. CTICD -8%. GME -6%. NBLX -5%. Comment! [On the Move]
Thursday, May 20, 2010, 9:05 AM Metal miners and solar stocks are among the big premarket losers: IRE -18%. NETS -14%. AGEN -10%. RSO -9%. RTP -8%. AEZS -8%. NGG -8%. ALU -8%. ABK -8%. JASO -7%. MT -7%. TSL -7%. BHP -6%. CTIC -6%. YGE -6%. RCL -6%. STD -6%. STO -6%. CENX -6%. VALE -5%. VVUS -5%. KERX -5%. CRXX -5%. MTL -5%. AWC -5%. DRYS -5%. GOLD -5%. AIB -5%. LVS -5%. STM -5%. SIRI -5%. BBVA -5%. CLF -4%. 4 Comments
Tuesday, May 18, 2010, 9:00 AM Premarket gainers: SPRD +19%. CTIC +10%. AGEN +7%. BZH +6%. YRCW +6%. VVUS +6%. FRX +6%. MGM +5%. STD +5%. LDK +5%. DKS +4%.
Losers: BAK -10%. FIS -6%. PUK -4%. Comment!
Wednesday, May 12, 2010, 9:00 AM Premarket gainers: ACHN +19%. AEZS +13%. AGEN +12%. HNSN +7%. VICL +7%. ING +6%. FIS +5%. BIDU +4%. HBAN +4%. TSEM +4%.
Losers: ERTS -5%. MIC -5%. MS -4%. WWE -4%. Comment!
Friday, April 16, 2010, 9:00 AM Premarket gainers: PFWD +29%. LGF +9%. RBS +7%. TWO +6%. BSX +6%. AGEN +6%. XRTX +6%. IMGN +5%. PALM +4%. MAT +4%. IRE +4%.
Losers: ATEC -6%. AMD -5%. GOOG -5%. FHN -4%. Comment!
Thursday, April 15, 2010, 9:00 AM Premarket gainers: ME +38%. ANDS +25%. AEZS +20%. IDIX +16%. TSFG +15%. IOC +9%. PPHM +10%. ABK +8%. CPBY +8%. IMGN +8%. RNN +7%. SIRI +6%. XOM +6%. JOEZ +6%. END +5%. YRCW +5%. AVNR +5%. UPS +4%. MDVN +4%. SOLR +4%. SGY +4%.
Losers: SNTS -34%. TITN -13%. NEP -9%. SMOD -6%. REVU -6%. MAC -6%. MGM -6%. AGEN -4%. APA -4%. BPOP -4%. Comment!
Tuesday, April 13, 2010, 9:00 AM Premarket gainers: MIPI +183%. AGEN +42%. ABK +28%. CVM +20%. XOMA +19%. BPOP +16%. FNM +10%. KERX +8%. DCTH +7%. CROX +6%. TLB +5%. EXPE +5%. HK +5%. FRE +5%. AONE +4%.
Losers: CODI -8%. PALM -7%. MPW -4%. Comment!
Wednesday, October 21, 2009, 9:00 AM Premarket gainers: SLM +11%. SNDK +5%. YHOO +5%. ELN +4%.
Losers: AGEN -41%. TSFG -23%. PLCM -13%. ATI -7%. KEY -4%. GNBT -4%. STM -4%. BEE -4%. 1 Comment
Tuesday, August 4, 2009, 10:27 AM Stock deals are sending drug equities in different directions: Antigenics (AGEN) down 7.4% to $2.40 as it agrees to sell 4.4M shares at $2.28. Human Genome (HGSI) up 9.8% to $15.60 as it settles a public offering of 27M shares at $14. Comment!

Scott Matusow
Trade call alert - bought $AGEN @ 4.45, target opinion $4.90 Catalyst trade, first catalyst May 1 trial data
Apr 23, 1:26 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

bigfoot
Nice move by $AGEN again today, but I'm still way underwater on it.
3/19/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

timtrading
$AGEN is skyrocketting, anyone buy this stock? http://bit.ly/x4TQPQ
3/7/12
Reply (2)

• !Report Abuse
View all 2 replies
EliteYoda: Buyout rumors..GSK possibly, eventually. Also cheap on assets and potential Billions if $AGEN's QS-21 is approved at some point. Read filing
3/7/12
• !Report Abuse
timtrading: thanks, yah. buy the rumors and sell the news.
3/8/12
• !Report Abuse
Add a reply...

140 characters

EliteYoda
AGEN trading with greater volume recently. Possible upside catalysts coming soon for the company and stock in 2012. FDA approval possible.
1/13/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

EliteYoda
AGEN Q1 2011 loss at (0.05) compared to estimate of (0.04) but half the loss of (0.10) Q1 2010 and drug pipeline strong, pps could move up.
4/28/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

EliteYoda
For AGEN even if one of the vaccines with adjuvant gets fda approval, this stock could take off and sky rocket into tens of dollars a share
4/24/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Chun Bong Lai
Watch out these symbols: AMCF, AGEN, CAPS.PK, CVM, CYTK. DYAX, BFLY, CLSN, CYBE, DGIT, DX
2/8/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

EliteYoda
Hmm, ok guess not. AGEN down just pennies under $1 and I have no clue why. Anyone know why AGEN pps so stubborn to rise close to $1 ? cheers
1/28/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

EliteYoda
Look like $1 per share for AGEN here to stay.. any news on this company?
1/19/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

EliteYoda
Me thinks the AGEN buybacks to keep on the NASD have created a new floor at $1 ... next cure for cancer? Can you say BULLISH?! :P
10/7/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

timtrading
$AGEN is skyrocketting, anyone buy this stock? http://bit.ly/x4TQPQ
3/7/12
Reply (2)

• !Report Abuse
View all 2 replies
EliteYoda: Buyout rumors..GSK possibly, eventually. Also cheap on assets and potential Billions if $AGEN's QS-21 is approved at some point. Read filing
3/7/12
• !Report Abuse
timtrading: thanks, yah. buy the rumors and sell the news.
3/8/12
• !Report Abuse
Add a reply...

140 characters

AGEN Agenus

AGEN

Agenus